| Literature DB >> 17080581 |
Micha Loebermann, Volker Fingerle, Matthias Lademann, Carlos Fritzsche, Emil C Reisinger.
Abstract
Entities:
Mesh:
Substances:
Year: 2006 PMID: 17080581 PMCID: PMC3373081 DOI: 10.3201/eid1202.050765
Source DB: PubMed Journal: Emerg Infect Dis ISSN: 1080-6040 Impact factor: 6.883
Results of serologic tests at diagnosis and during follow-up*
| Time (d) after onset of symptoms | ||||||
|---|---|---|---|---|---|---|
| IgM | IgG | IgM | IgG | IgM | IgG | |
| 6 | Negative (<1:20) | Negative (<1:32) | Negative | Negative | Negative | Negative |
| 10 | ND | ND | Positive | Negative | ND | ND |
| 28 | Positive (1:40) | Negative (1:32) | Positive | Negative | Positive | Negative |
| 107 | Positive (1:20) | Negative (<1:32) | Positive | Negative | Positive | Negative |
| 380 | Negative (<1:20) | Negative (<1:32) | Equivocal | Negative | Positive | Negative |
*Symptoms (fever, headache, myalgia) started 6 days before presentation. IFA, immunofluorescent assay; ELISA, enzyme-linked immunosorbent assay; Ig, immunoglobulin; ND, not done. †Genzyme Virotech, Germany. Positive titers: IgM >1:20, IgG >1:64. ‡Behring, Germany. §In-house Immunoblot, Max von Pettenkofer-Institut, Munich, Germany.